JP2011500151A - 血栓切除および軟質残屑物を除去する装置 - Google Patents
血栓切除および軟質残屑物を除去する装置 Download PDFInfo
- Publication number
- JP2011500151A JP2011500151A JP2010528914A JP2010528914A JP2011500151A JP 2011500151 A JP2011500151 A JP 2011500151A JP 2010528914 A JP2010528914 A JP 2010528914A JP 2010528914 A JP2010528914 A JP 2010528914A JP 2011500151 A JP2011500151 A JP 2011500151A
- Authority
- JP
- Japan
- Prior art keywords
- wire
- helical
- core
- catheter
- suction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013151 thrombectomy Methods 0.000 title description 7
- 239000000463 material Substances 0.000 claims abstract description 99
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 69
- 238000001802 infusion Methods 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims description 31
- 239000003978 infusion fluid Substances 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 16
- 239000011295 pitch Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 239000002657 fibrous material Substances 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 abstract description 76
- 238000005086 pumping Methods 0.000 abstract description 34
- 230000009471 action Effects 0.000 abstract description 21
- 208000007536 Thrombosis Diseases 0.000 abstract description 19
- 210000005166 vasculature Anatomy 0.000 abstract description 12
- 239000012530 fluid Substances 0.000 description 76
- 238000004804 winding Methods 0.000 description 45
- 238000005520 cutting process Methods 0.000 description 44
- 230000033001 locomotion Effects 0.000 description 33
- 238000006073 displacement reaction Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 17
- 230000008901 benefit Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 238000013461 design Methods 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 239000002699 waste material Substances 0.000 description 13
- 230000005540 biological transmission Effects 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 10
- 108010073385 Fibrin Proteins 0.000 description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 229950003499 fibrin Drugs 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000000835 fiber Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 238000005452 bending Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 6
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 229940112869 bone morphogenetic protein Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 4
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 4
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 4
- 229910001000 nickel titanium Inorganic materials 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 210000003484 anatomy Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 229940096397 interleukin-8 Drugs 0.000 description 3
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 101000962498 Macropis fulvipes Macropin Proteins 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000002942 anti-growth Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- IYOZTVGMEWJPKR-YWRZDDHQSA-N C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 Chemical compound C1C[C@@H](C(N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-YWRZDDHQSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940123228 Collagen inhibitor Drugs 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101100244894 Sus scrofa PR39 gene Proteins 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- -1 alcohol amino acids Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940072645 coumadin Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960001318 fondaparinux Drugs 0.000 description 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000009347 mechanical transmission Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- KDLHZDBZIXYQEI-OIOBTWANSA-N palladium-103 Chemical compound [103Pd] KDLHZDBZIXYQEI-OIOBTWANSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000005365 phosphate glass Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940028869 ticlid Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320758—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a rotating cutting instrument, e.g. motor driven
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3203—Fluid jet cutting instruments
- A61B17/32037—Fluid jet cutting instruments for removing obstructions from inner organs or blood vessels, e.g. for atherectomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320783—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions through side-hole, e.g. sliding or rotating cutter inside catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00681—Aspects not otherwise provided for
- A61B2017/00685—Archimedes screw
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22038—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with a guide wire
- A61B2017/22039—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with a guide wire eccentric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B2017/320733—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a flexible cutting or scraping element, e.g. with a whip-like distal filament member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B2017/320741—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions for stripping the intima or the internal plaque from a blood vessel, e.g. for endarterectomy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320758—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a rotating cutting instrument, e.g. motor driven
- A61B2017/320766—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a rotating cutting instrument, e.g. motor driven eccentric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2217/00—General characteristics of surgical instruments
- A61B2217/002—Auxiliary appliance
- A61B2217/005—Auxiliary appliance with suction drainage system
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
Abstract
Description
本特許文書は、2004年4月27日に出願されたジョン イー.ナシュらによる「Thrombectomy and Soft Debris Removal Devices」という名称の米国特許出願第10/832830号の一部継続出願である、2007年5月21日に出願された同時係属中で権利者が共通の米国特許出願第11/751443号の一部継続出願である。これら先の出願の全体の内容は、参照により明示的に組込まれる。
Maschに付与された米国特許第4728319号は、血管内で閉塞物を切断するためのカテーテルを開示しており、カテーテルは、閉塞物を断片に切断するための球状切断ヘッドを遠位端に有する。カテーテルは、さらに切断機構に酸素添加注入液を送出して、切断機構から残屑物を洗い流し、切断手段を清浄化する手段を特徴とする。カテーテルシステムは、断片を含む流体がカテーテルを通して排出されるように、負圧がそこを通して引出される排出通路を特徴とする。Maschはさらに、負圧印加に加えてまたはその代わりに、螺旋ポンピング構造が使用されて、残屑物が、近位に、かつ、処置部位から離れるように搬送されてもよいと記載している。螺旋ポンプを使用する実施形態では、内側および外側チューブの隣接面上の反対まわりの螺旋の間の相互作用がポンピング動作を引き起こす。
一実施形態では、カテーテルアセンブリは、1対の回転式螺旋ポンプを特徴とし、螺旋ポンプは吸引および注入液送出機能を提供し、別個の回転動力源(たとえば、電気モータ、空気タービン、水圧タービンなど)により独立に作動してもよい。ある実施形態では、螺旋ポンプ機構(注入および吸引)のそれぞれ用のロータは、単一の回転動力源に作動可能に結合されるが、(たとえば、独立の伝達機構(たとえば、クラッチパック、調整可能なまたは固定の歯車装置)の実装によって)それぞれは独立に作動してもよい。
注入液送出を組込むこれらの実施形態では、流体通路は、注入流体源(たとえば、リザーバ、ボトルまたは供給体など)で始まり、注入流体源は、好ましくは患者の近くに位置する、最も好ましくは、ポンプを作動することなく実質的に前方への自由な流れが発生するほどには高くはないが、リザーバに自由な流体流れが逆流するのを防止するために、患者の上方の高さに位置する。注入ポンプ38は注入流体を引込み加圧する。
生物活性成分の例
遺伝物質を含むまたは含まないアデノウイルス
アルコール
アミノ酸
L−アルギニン
血管形成薬
アンギオテンシン変換酵素抑制薬(ACE抑制薬)
アンギオテンシンII拮抗薬
血管形成抑制薬剤
抗不整脈薬
抗菌物質
抗生物質
エリスロマイシン
ペニシリン
抗凝固剤
ヘパリン
反成長因子
抗炎症剤
デキサメタゾン
アスピリン
ヒドロコルチゾン
酸化防止剤
抗血小板剤
ホルスコリン
GPIIb−IIIa抑制薬
eptiflbatide
抗成長剤
ローキナーゼ抑制剤
(+)−trans−4−(1−aminoethyl)−1−(4−pyridylcarbamoyl)
シクロヘキサン
拒絶反応抑制剤
ラパマイシン
抗再狭窄薬
アデノシンA2A受容体作用薬
アンチセンス
抗けいれん薬
リドカイン
ニトログリセリン
Nicarpidine
抗血栓薬
アルガトロバン
フォンダパリヌクス
ヒルジン
GPIIb/IIIa抑制薬
抗ウイルス剤
動脈形成剤
酸性線維芽細胞成長因子(aFGF)
アンギオジェニン
アンギオトロピン
塩基性線維芽細胞成長因子(bFGF)
骨形成タンパク質(BMP)
上皮成長因子(EGF)
フィブリン
顆粒球マクロファージコロニー刺激因子(GM−CSF)
肝細胞成長因子(HGF)
HIF−1
インシュリン成長因子−1(IGF−1)
インターロイキン−8(IL−8)
MAC−1
ニコチン酸アミド
血小板由来内皮細胞成長因子(PD−ECGF)
血小板由来成長因子(PDGF)
トランスフォーミング成長因子アルファおよびベータ(TGF−α、TGF−β)
腫瘍壊死因子アルファ(TNF−α)
血管内皮細胞成長因子(VEGF)
血管透過性因子(VPF)
細菌
β遮断薬
血液凝固因子
骨形成タンパク質(BMP)
カルシウムチャネル遮断薬
発ガン物質
細胞
細胞物質
脂肪細胞
血球
骨髄
変質受容体または結合部位を有する骨髄細胞
内皮細胞
上皮細胞
繊維芽細胞
遺伝子的に変質した細胞
糖タンパク質
成長因子
脂質
リポソーム
マクロファージ
間葉系幹細胞
前駆細胞
網状赤血球
骨格筋細胞
平滑筋細胞
幹細胞
小胞
化学療法薬
セラミド
タクソール
シスプラチン
コレステロール低下薬
コンドロイチン
コラーゲン抑制剤
コロニー刺激因子
クーマディン
サイトカインプロスタグランジン
象牙質
エトレチナート
遺伝物質
グルコサミン
グリコサミノグリカン
GPIIb−IIIa阻害薬
L−703、081
顆粒球マクロファージコロニー刺激因子(GM−CSF)
成長因子拮抗薬または阻害薬
成長因子
骨形成タンパク質(BMP)
核結合因子A
内皮細胞成長因子(ECGF)
上皮成長因子(EGF)
線維芽細胞成長因子(FGF)
肝細胞成長因子(HGF)
インシュリン成長因子(例えば、IGF−1)
神経成長因子(NGF)
血小板由来成長因子(PDGF)
組換型NGF(rhNGF)
腫瘍壊死因子(TNF)
トランスフォーミング成長因子アルファ(TGF−α)
トランスフォーミング成長因子ベータ(TGF−β)
血管内皮細胞成長因子(VEGF)
血管透過性因子(UPF)
酸性線維芽細胞成長因子(aFGF)
塩基性線維芽細胞成長因子(bFGF)
線維芽細胞成長因子(EGF)
肝細胞成長因子(HGF)
インシュリン成長因子−1(IGF−1)
血小板由来内皮細胞成長因子(PD−ECGF)
腫瘍壊死因子アルファ(TNF−α)
成長ホルモン
ヘパリン硫酸プロテオグリカン
HMC−CoA還元酵素阻害薬(スタチン)
ホルモン
エリスロポイエチン
Immoxidal
免疫抑制剤
炎症メディエーター
インシュリン
インターロイキン
インターロイキン−8(IL−8)
Interlukins
脂質低下薬
リポタンパク質
低分子ヘパリン
リンパ球
リジン
MAC−1
メチル化抑制薬
モルフォゲン
酸化窒素(NO)
ヌクレオチド
ペプチド
ポリフェノール
PR39
プロテイン
プロスタグランジン
プロテオグリカン
パールカン
放射性物質
ヨウ素−125
ヨウ素−131
インジウム−192
パラジウム103
放射性医薬品
2次メッセンジャー
セラミド
ソマトメジン
スタチン
幹細胞
ステロイド
トロンビン
トロンビン阻害薬
血栓溶解薬
Ticlid
チロシンキナーゼ抑制薬
ST638
AG−17
血管拡張薬
ヒスタミン
ホルスコリン
ニトログリセリン
ビタミン
E
C
イースト
Ziphi fructus
注入剤はまた、流体のみの送出の代わりに固体または半固体を含んでもよい。固体は溶液中に懸濁されてもよい。いずれにしても、固体は、螺旋ポンプシステムでの使用に許容可能な粒子径、すなわち、提供される螺旋ポンプを通して送出できる粒子径であるべきである。送出されてもよい固体または半固体の例の非網羅的なリストが表2に列挙されている。
本発明により送出可能な固体または半固体の例
アルギナート
バイオガラス
カルシウム
リン酸カルシウム
セラミック
キチン
キトサン
シアノアクリレート
コラーゲン
ダクロン
脱灰された骨
エラスチン
フィブリン
ゼラチン
ガラス
金
ヒアルロン酸
ヒドロゲル
ヒドロキシアパタイト
ヒドロキシエチルメタクリレート
ヒアルロン酸
リポソーム
間充織細胞
ニチノール
骨芽細胞
酸化再生セルロース
リン酸塩ガラス
ポリエチレングリコール
ポリエステル
多糖類
ポリビニルアルコール
血小板、血球
Radiopacifier
塩
シリコン
絹
鋼(例えば、ステンレス鋼)
合成高分子
トロンビン
チタン
表のグループおよびサブグループの記載物は例示であり、単に便宜上のものである。グループ分けは、グループ中の任意の物質の好ましい使用または使用の制限を含まない。たとえば、表1では、グループ分けは単に参照のためであり、いずれの点でも制限することを意味しない(たとえば、タクソール配合物は化学療法の適用ならびに抗再狭窄コーティングのために使用されることが認識される)。さらに、表は、多くの他の薬物および薬物グループが目下の実施形態での使用について考えられるため、全てを網羅的でない。既存と開発中の両方の多くの治療の自然発生形態および合成形態が存在し、表は両方の形式を含むことを意味する。
不均衡な流体流量による過剰な失血および/または管腔の圧壊を防止するための配慮が払われてもよい。
本発明のある実施形態では、たとえば、図2Aに示すように、吸引ポンプ40および注入ポンプ38は単一ドライブシャフト12から切り離されて駆動され、ドライブシャフトはドライブシャフトに加えられる力(たとえば、電気モータ、空気タービン、水圧タービンなど)により推進される。とりわけこの実施形態によって、安全機構62の組込みが有益である可能性がある。作動時、ドライブシャフト12の作動は、注入ポンプ38および吸引ポンプ40の両方を同時に回転させるが、アセンブリの遠位端を通る注入液送出は、好ましくは、説明されるように、安全機構62が作動するまで始動されない。
アセンブリ1は、アセンブリの遠位端にあり、プロシジャのために患者内に導入される作業ヘッド400を特徴とする。作業ヘッドの例は図4、5、および6に示される。図4に見られるように、作業ヘッド400は、図2Aの吸引ポンプ40に作動可能に接続される。作業ヘッドは、吸引カテーテルジャケット53に物理的に取り付けられたキャップ402およびキャップ内で回転する吸引コイル状部材49の螺旋コイルを特徴とする。図4の作業ヘッドは、生体の血管424内に配置された状態で示され、アセンブリは、ここでは病変部、付着物または狭窄である可能性がある閉塞物質426を有するものとして示される処置部位に達するために、ガイドワイヤ430上をモノレールとして進められている。ガイドワイヤの遠位端にまたはその近くには、図示するように、遠位保護手段444があってもよい。遠位保護手段は、バルーン(図示なし)によって流体の自由な流れを防止することなどによって、または別法として、任意の残屑物または緩んだ閉塞物質426を取り込むためのフィルタ機構の使用などによって、残屑物が処置部位から離れて移動することを防止するのに役立つ。装置の使用は、上述したように、吸引ポンプの作動による流体および閉塞物質の安全な吸引に依存して、遠位保護の使用を必要としないことが認識される。
注入ポンプと同様に、装置は、螺旋ポンプ340を形成するために、中空管腔コアチューブ342に巻き付けられ、かつ、カテーテルジャケット358内に収容された吸引巻線346を特徴とする。モータ326Bが回転すると、コイル状部材を形成する吸引巻線346が、カテーテルジャケット358内で回転し、残屑物の近位への吸引が生じ、残屑物は、その後、廃棄物管腔356によって廃棄物リザーバ354の方に送られてもよい。中空管腔コア342は、コアチューブ駆動部742、ギア駆動部702、およびコアチューブモータ326Cによって駆動されると、静止した位置に保持されうるか、または、任意の適した速度または方向で作動しうる。
本発明は、所定の場所に標準ガイドワイヤを具備するかまたは具備しないかのいずれでも作動してもよい。ガイドワイヤが器具の作動中に所定場所にない場合、標準ガイドワイヤは、当分野で既知の技法を使用して、処置部位への(たとえば、蛇行した血管構造を通る)装置のナビゲーションを補助するために利用されてもよい。所定場所に置かれると、ガイドワイヤは、本発明の操作を可能にするために取り除かれてもよい。あるいは、装置は、当技術分野で知られているカテーテル法を使用して、標準ガイドワイヤの補助なしで、所定位置に配置されてもよい。
Claims (22)
- 生体内の血管、管または管腔から閉塞物質の堆積物を除去するフレキシブルカテーテルシステムであって、
回転螺旋吸引ポンプを備え、前記回転螺旋吸引ポンプは螺旋ワイヤ、コアおよびカテーテルジャケットを備え、前記カテーテルジャケットは前記螺旋ワイヤを囲むものであり、前記螺旋ワイヤは螺旋配置で前記コアに巻き付けられ、さらに、前記螺旋ワイヤは螺旋回転動力源によって駆動されて、前記コアとは独立に作動するフレキシブルカテーテルシステム。 - 前記螺旋ワイヤが前記回転動力源によって駆動されたとき、前記コアは回転しないように構成される請求項1に記載のフレキシブルカテーテルシステム。
- 前記コアは、前記螺旋ワイヤの前記作動と同じ方向に回転するように構成される請求項1に記載のフレキシブルカテーテルシステム。
- 前記コアは、前記螺旋ワイヤの前記作動と反対方向に回転するように構成される請求項1に記載のフレキシブルカテーテルシステム。
- 前記コア回転動力源は、前記螺旋回転動力源とは独立している請求項4に記載のフレキシブルカテーテルシステム。
- 前記コアの独立した回転は、フレキシブルカテーテルシステムの遠位端および作業ヘッドを変位させて、閉塞物質の除去を改善する作用を有する請求項4に記載のフレキシブルカテーテルシステム。
- 前記コアは、中空であり、また、注入ポンプから、血管、管または管腔への注入流体の送出を可能にするように構成される請求項1に記載のフレキシブルカテーテルシステム。
- 前記注入ポンプは、前記螺旋コイルと前記コアのいずれかとは独立に作動するように構成される請求項7に記載のフレキシブルカテーテルシステム。
- ガイドワイヤ追従手段をさらに備える請求項1に記載のフレキシブルカテーテルシステム。
- 遠位保護をさらに備える請求項1に記載のフレキシブルカテーテルシステム。
- 生体内の血管、管または管腔から閉塞物質の堆積物を除去する方法であって、
(a)螺旋ワイヤ、コアおよびカテーテルジャケットを備えるフレキシブルカテーテルシステムであって、前記カテーテルジャケットは前記螺旋ワイヤを囲み、前記螺旋ワイヤは、前記コアに巻き付けられ、さらに、前記螺旋ワイヤは、回転動力源によって駆動されて、前記カテーテルジャケット内で前記コア管腔と独立に作動する、フレキシブルカテーテルシステムを設けること、
(b)ガイドワイヤを使用して、前記フレキシブルカテーテルシステムを生体内に挿入すること、および、
(c)前記生体から前記閉塞物質を除去するために、前記回転動力源を作動させることを含む方法。 - 線維性物質のフレキシブルコンベヤーであって、
コイルワイヤと、中心コアとを備える螺旋コンベヤーを備え、前記螺旋コンベヤーは、ジャケット内で回転するように構成され、前記螺旋コンベヤーが回転する際に線維性物質が詰るのを防止すべく、前記螺旋コンベヤーは、前記ロータ直径の50%程度の大きさのクリアランスを前記ジャケット内に有するフレキシブルコンベヤー。 - 前記螺旋コンベヤーは、前記クリアランスによる漏洩を克服するために、十分に高速で回転するように構成される請求項12に記載のフレキシブルコンベヤー。
- 生体内の血管、管または管腔から閉塞物質の堆積物を除去するフレキシブルカテーテルシステムであって、螺旋コイルを収容するカテーテルジャケットを備えるカテーテルと、少なくとも前記螺旋コイルをコアワイヤとは独立して回転させるように構成された回転動力源とを備え、ガイドワイヤおよびガイドワイヤ追従手段をさらに備え、前記カテーテルジャケットの遠位領域は、前記螺旋コイルが作動している間、前記ガイドワイヤから横方向に変位するように構成されるフレキシブルカテーテルシステム。
- 前記カテーテルは、近位領域、遠位領域および前記近位領域と前記遠位領域との間に延在するハウジングとを備え、前記ハウジングは、前記吸引カテーテルジャケットを備え、かつ、前記遠位領域の入口領域および前記近位領域の出口領域を有する管腔を画定し、さらに、前記ガイドワイヤ追従手段は、前記カテーテルの前記遠位領域における少なくとも2つの離間した点で前記ガイドワイヤに隣接して前記カテーテルを保持し、前記螺旋ワイヤ内で前記カテーテルジャケットの長さに沿って延在する中心コア管をなおさらに備え、前記中心コア管は、前記螺旋ワイヤに直接結合されない請求項14に記載のフレキシブルカテーテルシステム。
- 前記回転動力は、いろいろな速度パターンで作動する請求項15に記載のフレキシブルカテーテルシステム。
- 前記螺旋コイルワイヤは、螺旋ピッチの異なる複数のゾーンを備える請求項15に記載のフレキシブルカテーテルシステム。
- 前記中心コア管は、中実のワイヤまたはフィラメントである請求項15に記載のフレキシブルカテーテルシステム。
- 前記回転動力は、可変速度パターンで作動する請求項1に記載のフレキシブルカテーテルシステム。
- 前記螺旋コイルワイヤは、螺旋ピッチの異なる複数のゾーンを備える請求項1に記載のフレキシブルカテーテルシステム。
- 生体内の血管、管または管腔から閉塞物質の堆積物を除去するフレキシブルカテーテルシステムであって、回転螺旋吸引ポンプを備え、前記回転螺旋吸引ポンプは、螺旋ワイヤ、コアおよびカテーテルジャケットを備え、前記カテーテルジャケットは前記螺旋ワイヤを囲み、前記螺旋ワイヤは、螺旋配置で前記コアに巻き付けられ、さらに、前記螺旋ワイヤは、螺旋回転動力源によって駆動され、さらに、前記回転動力は、可変速度パターンで作動するフレキシブルカテーテルシステム。
- 注入物の補助なしで、生体内の血管、管または管腔から閉塞物質の堆積物を除去するフレキシブルカテーテルシステムであって、回転螺旋吸引ポンプを備え、前記回転螺旋吸引ポンプは、螺旋ワイヤ、コアおよびカテーテルジャケットを備え、前記カテーテルジャケットは前記螺旋ワイヤを囲み、前記螺旋ワイヤは、螺旋配置で前記コアに巻き付けられ、前記コアと独立に回転することができ、前記螺旋ワイヤは、回転動力源によって駆動されるフレキシブルカテーテルシステム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/871,908 US8920402B2 (en) | 2004-04-27 | 2007-10-12 | Thrombectomy and soft debris removal device |
US11/871,908 | 2007-10-12 | ||
PCT/US2008/073171 WO2009097008A1 (en) | 2007-10-12 | 2008-08-14 | Thrombectomy and soft debris removal device |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011500151A true JP2011500151A (ja) | 2011-01-06 |
JP2011500151A5 JP2011500151A5 (ja) | 2011-09-22 |
JP5429714B2 JP5429714B2 (ja) | 2014-02-26 |
Family
ID=39319008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010528914A Active JP5429714B2 (ja) | 2007-10-12 | 2008-08-14 | 血栓切除および軟質残屑物を除去する装置 |
Country Status (4)
Country | Link |
---|---|
US (3) | US8920402B2 (ja) |
EP (1) | EP2187815B1 (ja) |
JP (1) | JP5429714B2 (ja) |
WO (1) | WO2009097008A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016529968A (ja) * | 2013-07-26 | 2016-09-29 | カーディオバスキュラー システムズ, インコーポレイテッド | 装置を交換することなくアテレクトミおよびその後のバルーン血管形成を行うための装置、システムおよび方法 |
WO2018051894A1 (ja) * | 2016-09-16 | 2018-03-22 | テルモ株式会社 | 医療デバイス |
WO2019188656A1 (ja) * | 2018-03-29 | 2019-10-03 | テルモ株式会社 | 医療デバイスの制御装置及び流体の流量を制御する方法 |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8920402B2 (en) | 2004-04-27 | 2014-12-30 | The Spectranetics Corporation | Thrombectomy and soft debris removal device |
US7959608B2 (en) * | 2004-04-27 | 2011-06-14 | The Spectranetics Corporation | Thrombectomy and soft debris removal device |
WO2008097993A2 (en) | 2007-02-05 | 2008-08-14 | Boston Scientific Limited | Thrombectomy apparatus and method |
DE202007011066U1 (de) * | 2007-08-08 | 2007-10-18 | Key Safety Systems, Inc., Sterling Heights | Sicherheitsgurtschloss |
US20090138031A1 (en) * | 2007-11-24 | 2009-05-28 | Tsukernik Vladimir B | Thrombectomy catheter with a helical cutter |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US9672471B2 (en) | 2007-12-18 | 2017-06-06 | Gearbox Llc | Systems, devices, and methods for detecting occlusions in a biological subject including spectral learning |
US20090163856A1 (en) * | 2007-12-19 | 2009-06-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Treatment indications informed by a prior implant information |
US9510854B2 (en) | 2008-10-13 | 2016-12-06 | Boston Scientific Scimed, Inc. | Thrombectomy catheter with control box having pressure/vacuum valve for synchronous aspiration and fluid irrigation |
US20100114081A1 (en) | 2008-11-05 | 2010-05-06 | Spectranetics | Biasing laser catheter: monorail design |
US9408665B2 (en) * | 2008-12-12 | 2016-08-09 | The Spectranetics Corporation | Offset catheter |
US8702773B2 (en) | 2008-12-17 | 2014-04-22 | The Spectranetics Corporation | Eccentric balloon laser catheter |
US9101884B2 (en) * | 2010-02-18 | 2015-08-11 | NAB & Associates, Inc. | Enhanced spiral-wound membrane filtration |
US8551130B2 (en) | 2010-02-18 | 2013-10-08 | Cardiovascular Systems, Inc. | Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit |
US9050414B2 (en) | 2010-02-19 | 2015-06-09 | Cardiovascular Systems, Inc. | Systems and methods for mixing therapeutic agents before and/or during administration |
BR112012022948B1 (pt) * | 2010-03-11 | 2020-05-26 | Advanced Catheter Therapies, Inc. | Dispositivo para aterectomia |
SG184362A1 (en) * | 2010-03-30 | 2012-11-29 | Singapore Health Serv Pte Ltd | Cutting device for cutting tissue |
CN107260304B (zh) | 2011-02-24 | 2024-05-24 | 爱克斯莫医疗有限公司 | 用于组织切除术的混合导管 |
CN102125453B (zh) * | 2011-04-24 | 2012-04-18 | 广州大学 | 一种清理血栓的血管机器人 |
WO2013016056A2 (en) * | 2011-07-25 | 2013-01-31 | Acclarent, Inc. | Devices and methods for transnasal dilation and irrigation of the sinuses |
US9095364B2 (en) * | 2011-07-28 | 2015-08-04 | Acclarent, Inc. | Device and method for dilating an airway stenosis |
EP2841159B1 (en) * | 2012-04-24 | 2017-07-26 | Light Instruments Ltd. | An electromagnetic shield for a dental laser hand piece |
US9381062B2 (en) | 2012-05-31 | 2016-07-05 | Covidien Lp | Electro-mechanical intravascular device |
US9050127B2 (en) * | 2012-06-27 | 2015-06-09 | Boston Scientific Limited | Consolidated atherectomy and thrombectomy catheter |
US9549666B2 (en) | 2012-11-10 | 2017-01-24 | Curvo Medical, Inc. | Coaxial micro-endoscope |
US9233225B2 (en) | 2012-11-10 | 2016-01-12 | Curvo Medical, Inc. | Coaxial bi-directional catheter |
US9295479B2 (en) * | 2013-03-14 | 2016-03-29 | Spinal Stabilization Technologies, Llc | Surgical device |
EP3620203A1 (en) | 2013-03-15 | 2020-03-11 | Insera Therapeutics, Inc. | Vascular treatment devices |
US10271869B2 (en) | 2014-03-01 | 2019-04-30 | Rex Medical, L.P. | Atherectomy device |
US9433427B2 (en) | 2014-04-08 | 2016-09-06 | Incuvate, Llc | Systems and methods for management of thrombosis |
US9248221B2 (en) | 2014-04-08 | 2016-02-02 | Incuvate, Llc | Aspiration monitoring system and method |
EP3915503A3 (en) | 2014-05-18 | 2022-03-16 | Eximo Medical Ltd. | System for tissue ablation using pulsed laser |
US9883877B2 (en) | 2014-05-19 | 2018-02-06 | Walk Vascular, Llc | Systems and methods for removal of blood and thrombotic material |
US10492863B2 (en) | 2014-10-29 | 2019-12-03 | The Spectranetics Corporation | Laser energy delivery devices including laser transmission detection systems and methods |
EP3212103B1 (en) | 2014-10-29 | 2021-12-15 | The Spectranetics Corporation | Laser energy delivery devices including laser transmission detection systems and methods |
US10463389B2 (en) | 2014-12-27 | 2019-11-05 | Rex Medical, L.P. | Atherectomy device |
US10433868B2 (en) | 2014-12-27 | 2019-10-08 | Rex Medical, L.P. | Artherectomy device |
USD775728S1 (en) | 2015-07-02 | 2017-01-03 | The Spectranetics Corporation | Medical device handle |
US10702292B2 (en) | 2015-08-28 | 2020-07-07 | Incuvate, Llc | Aspiration monitoring system and method |
US10561440B2 (en) | 2015-09-03 | 2020-02-18 | Vesatek, Llc | Systems and methods for manipulating medical devices |
US11253292B2 (en) | 2015-09-13 | 2022-02-22 | Rex Medical, L.P. | Atherectomy device |
US10596354B2 (en) * | 2015-09-25 | 2020-03-24 | Mark Taber | Guide wires, catheters, and guide wire catheter systems and methods |
US20170100142A1 (en) | 2015-10-09 | 2017-04-13 | Incuvate, Llc | Systems and methods for management of thrombosis |
US10226263B2 (en) | 2015-12-23 | 2019-03-12 | Incuvate, Llc | Aspiration monitoring system and method |
CN108697423A (zh) | 2016-02-16 | 2018-10-23 | 伊瑟拉医疗公司 | 抽吸装置和锚定的分流装置 |
EP3422963B1 (en) | 2016-03-03 | 2022-06-29 | Boston Scientific Scimed Inc. | Accessory devices for use with catheters |
US10307175B2 (en) | 2016-03-26 | 2019-06-04 | Rex Medical, L.P | Atherectomy device |
US10492805B2 (en) | 2016-04-06 | 2019-12-03 | Walk Vascular, Llc | Systems and methods for thrombolysis and delivery of an agent |
CN109414292A (zh) | 2016-05-05 | 2019-03-01 | 爱克斯莫医疗有限公司 | 用于切除和/或消融不需要的组织的装置和方法 |
US10953204B2 (en) | 2017-01-09 | 2021-03-23 | Boston Scientific Scimed, Inc. | Guidewire with tactile feel |
EP3585284B1 (en) | 2017-02-21 | 2022-10-26 | Boston Scientific Scimed, Inc. | Thrombectomy catheter with helical guidewire |
US11224458B2 (en) | 2017-04-10 | 2022-01-18 | The Regents Of The University Of Michigan | Hydrodynamic vortex aspiration catheter |
EP4201346B1 (en) * | 2017-04-10 | 2024-11-06 | The Regents Of The University Of Michigan | Hydrodynamic vortex aspiration catheter |
WO2018204704A1 (en) | 2017-05-03 | 2018-11-08 | Medtronic Vascular, Inc. | Tissue-removing catheter |
US11690645B2 (en) | 2017-05-03 | 2023-07-04 | Medtronic Vascular, Inc. | Tissue-removing catheter |
WO2018215840A1 (en) | 2017-05-23 | 2018-11-29 | Asahi Intecc Co., Ltd. | Assistive jet aspiration thrombectomy catheter and method of using same |
US11389191B2 (en) * | 2017-05-31 | 2022-07-19 | Terumo Kabushiki Kaisha | Device handle for a medical device |
US10888350B2 (en) * | 2017-05-31 | 2021-01-12 | Terumo Kabushiki Kaisha | Device handle for a medical device |
EP4233989A3 (en) | 2017-06-07 | 2023-10-11 | Shifamed Holdings, LLC | Intravascular fluid movement devices, systems, and methods of use |
CN114983518A (zh) * | 2017-06-30 | 2022-09-02 | 上海蓝脉医疗科技有限公司 | 机械血栓清除装置 |
US10328278B2 (en) | 2017-11-02 | 2019-06-25 | Isoray Medical, Inc | Device for loading brachytherapy seeds into implantation sleeves |
US11511103B2 (en) | 2017-11-13 | 2022-11-29 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
USD847864S1 (en) | 2018-01-22 | 2019-05-07 | Insera Therapeutics, Inc. | Pump |
JP7410034B2 (ja) | 2018-02-01 | 2024-01-09 | シファメド・ホールディングス・エルエルシー | 血管内血液ポンプならびに使用および製造の方法 |
US11678905B2 (en) | 2018-07-19 | 2023-06-20 | Walk Vascular, Llc | Systems and methods for removal of blood and thrombotic material |
EP4434477A2 (en) | 2018-11-16 | 2024-09-25 | Medtronic Vascular Inc. | Tissue-removing catheter |
WO2020150591A1 (en) * | 2019-01-18 | 2020-07-23 | Boston Scientific Scimed, Inc. | Gearbox for atherectomy system |
US11819236B2 (en) | 2019-05-17 | 2023-11-21 | Medtronic Vascular, Inc. | Tissue-removing catheter |
US11291468B2 (en) * | 2019-06-18 | 2022-04-05 | Boston Scientific Scimed, Inc. | Atherectomy system adapted to free a stuck atherectomy burr |
JP2022540616A (ja) | 2019-07-12 | 2022-09-16 | シファメド・ホールディングス・エルエルシー | 血管内血液ポンプならびに製造および使用の方法 |
WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
EP4034184A4 (en) | 2019-09-25 | 2023-10-18 | Shifamed Holdings, LLC | CATHETER BLOOD PUMP AND COLLAPSIBLE BLOOD LINES |
EP4034192A4 (en) | 2019-09-25 | 2023-11-29 | Shifamed Holdings, LLC | INTRAVASCULAR BLOOD PUMP SYSTEMS AND METHODS OF USE AND CONTROL THEREOF |
EP4034221A4 (en) | 2019-09-25 | 2023-10-11 | Shifamed Holdings, LLC | CATHETER BLOOD PUMPS AND FOLDABLE PUMP HOUSINGS |
WO2021122253A1 (en) * | 2019-12-20 | 2021-06-24 | Koninklijke Philips N.V. | Atherectomy devices including sealed drive shafts |
WO2021158965A1 (en) | 2020-02-07 | 2021-08-12 | 2Mg, Inc. | Devices and methods for removal of material in a vasculature |
CN111671491B (zh) * | 2020-07-14 | 2024-10-01 | 上海融脉医疗科技有限公司 | 一种血栓取出导管装置 |
EP4240460A4 (en) | 2020-11-09 | 2024-05-08 | Agile Devices, Inc. | CATHETER CONTROL DEVICES |
CA3210625A1 (en) | 2021-03-01 | 2022-09-09 | Scott J. Baron | Aspiration devices for treatment of thrombosis including expandable distal ends and systems and methods thereof |
US11717603B2 (en) | 2021-04-27 | 2023-08-08 | Contego Medical, Inc. | Thrombus aspiration system and methods for controlling blood loss |
JP2024524386A (ja) | 2021-06-28 | 2024-07-05 | インクイス メディカル,インコーポレーテッド | 閉塞性物質の除去を制御するための装置および方法 |
WO2023168336A2 (en) * | 2022-03-02 | 2023-09-07 | Xtract Medical, Inc. | Devices and methods for removing material from a patient |
US12038322B2 (en) | 2022-06-21 | 2024-07-16 | Eximo Medical Ltd. | Devices and methods for testing ablation systems |
WO2024016004A2 (en) * | 2022-07-14 | 2024-01-18 | Shifamed Holdings, Llc | Thrombus removal systems and associated methods |
US12053192B2 (en) | 2022-09-01 | 2024-08-06 | Endovascular Engineering, Inc. | Systems, devices, and methods for aspiration, including expandable structures and rotatable shafts |
CN116784941B (zh) * | 2023-08-25 | 2023-11-24 | 浙江归创医疗科技有限公司 | 一种柔性驱动轴及侵入器械 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0380872A (ja) * | 1989-05-12 | 1991-04-05 | Samuel Shiber | アテレクトミイ装置 |
US20050240146A1 (en) * | 2004-04-27 | 2005-10-27 | Nash John E | Thrombectomy and soft debris removal device |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196729A (en) * | 1977-12-23 | 1980-04-08 | Cunningham Joseph N | Device for perfusing a heart with blood supplied at constant pressure |
US4445509A (en) * | 1982-02-04 | 1984-05-01 | Auth David C | Method and apparatus for removal of enclosed abnormal deposits |
US4631052A (en) * | 1984-01-03 | 1986-12-23 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4589412A (en) * | 1984-01-03 | 1986-05-20 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US5653696A (en) * | 1984-05-14 | 1997-08-05 | Surgical Systems & Instruments, Inc. | Stent unclogging method |
US4979939A (en) * | 1984-05-14 | 1990-12-25 | Surgical Systems & Instruments, Inc. | Atherectomy system with a guide wire |
US5334211A (en) * | 1984-05-14 | 1994-08-02 | Surgical System & Instruments, Inc. | Lumen tracking atherectomy system |
US4781186A (en) * | 1984-05-30 | 1988-11-01 | Devices For Vascular Intervention, Inc. | Atherectomy device having a flexible housing |
US4592852A (en) | 1984-06-07 | 1986-06-03 | Enthone, Incorporated | Composition and process for treating plastics with alkaline permanganate solutions |
US4790813A (en) * | 1984-12-17 | 1988-12-13 | Intravascular Surgical Instruments, Inc. | Method and apparatus for surgically removing remote deposits |
US4686982A (en) * | 1985-06-19 | 1987-08-18 | John Nash | Spiral wire bearing for rotating wire drive catheter |
US4700705A (en) * | 1985-08-12 | 1987-10-20 | Intravascular Surgical Instruments, Inc. | Catheter based surgical methods and apparatus therefor |
US4790812A (en) * | 1985-11-15 | 1988-12-13 | Hawkins Jr Irvin F | Apparatus and method for removing a target object from a body passsageway |
US5000185A (en) * | 1986-02-28 | 1991-03-19 | Cardiovascular Imaging Systems, Inc. | Method for intravascular two-dimensional ultrasonography and recanalization |
US4696667A (en) * | 1986-03-20 | 1987-09-29 | Helmut Masch | Intravascular catheter and method |
US4728319A (en) * | 1986-03-20 | 1988-03-01 | Helmut Masch | Intravascular catheter |
US5350395A (en) * | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US4747821A (en) * | 1986-10-22 | 1988-05-31 | Intravascular Surgical Instruments, Inc. | Catheter with high speed moving working head |
US4749376A (en) * | 1986-10-24 | 1988-06-07 | Intravascular Surgical Instruments, Inc. | Reciprocating working head catheter |
US4850358A (en) * | 1986-11-14 | 1989-07-25 | Millar Instruments, Inc. | Method and assembly for introducing multiple devices into a biological vessel |
US4857045A (en) * | 1987-04-30 | 1989-08-15 | Schneider (Usa) Inc., A Pfizer Company | Atherectomy catheter |
US4857046A (en) * | 1987-10-21 | 1989-08-15 | Cordis Corporation | Drive catheter having helical pump drive shaft |
US4955882A (en) * | 1988-03-30 | 1990-09-11 | Hakky Said I | Laser resectoscope with mechanical and laser cutting means |
US5269751A (en) * | 1988-09-21 | 1993-12-14 | Josef Kaliman | Thrombectomy catheter for enlarging an artery |
US4950277A (en) * | 1989-01-23 | 1990-08-21 | Interventional Technologies, Inc. | Atherectomy cutting device with eccentric wire and method |
US5084052A (en) * | 1989-02-09 | 1992-01-28 | Baxter International Inc. | Surgical cutting instrument with plurality of openings |
US5728129A (en) * | 1989-02-17 | 1998-03-17 | American Biomed, Inc. | Distal atherectomy catheter |
US5431673A (en) * | 1989-02-17 | 1995-07-11 | American Biomed, Inc. | Distal atherectomy catheter |
US5087265A (en) * | 1989-02-17 | 1992-02-11 | American Biomed, Inc. | Distal atherectomy catheter |
US5226909A (en) * | 1989-09-12 | 1993-07-13 | Devices For Vascular Intervention, Inc. | Atherectomy device having helical blade and blade guide |
US5074841A (en) * | 1990-01-30 | 1991-12-24 | Microcision, Inc. | Atherectomy device with helical cutter |
US5267955A (en) * | 1990-05-10 | 1993-12-07 | Lake Region Manufacturing Company, Inc. | Atherectomy device |
US5395311A (en) * | 1990-05-14 | 1995-03-07 | Andrews; Winston A. | Atherectomy catheter |
US5195954A (en) * | 1990-06-26 | 1993-03-23 | Schnepp Pesch Wolfram | Apparatus for the removal of deposits in vessels and organs of animals |
CA2048120A1 (en) * | 1990-08-06 | 1992-02-07 | William J. Drasler | Thrombectomy method and device |
US5078722A (en) * | 1990-08-14 | 1992-01-07 | Cordis Corporation | Method and apparatus for removing deposits from a vessel |
US5242460A (en) * | 1990-10-25 | 1993-09-07 | Devices For Vascular Intervention, Inc. | Atherectomy catheter having axially-disposed cutting edge |
US5569275A (en) * | 1991-06-11 | 1996-10-29 | Microvena Corporation | Mechanical thrombus maceration device |
US5284486A (en) * | 1991-06-11 | 1994-02-08 | Microvena Corporation | Self-centering mechanical medical device |
US5261877A (en) * | 1991-07-22 | 1993-11-16 | Dow Corning Wright | Method of performing a thrombectomy procedure |
US5135483A (en) * | 1991-07-22 | 1992-08-04 | Dow Corning Wright Corporation | Atherectomy device with a removable drive system |
DE69218794T2 (de) | 1992-01-13 | 1997-07-10 | Schneider Usa Inc | Chirurgisches schneidinstrument |
US5267958A (en) * | 1992-03-30 | 1993-12-07 | Medtronic, Inc. | Exchange catheter having exterior guide wire loops |
FR2696924B1 (fr) | 1992-08-06 | 1995-01-06 | Domilens Laboratoires | Instrument chirurgical pour la fragmentation in situ d'un matériau vivant, notamment instrument de phaco-fragmentation ou phaco-émulsification. |
US5360432A (en) * | 1992-10-16 | 1994-11-01 | Shturman Cardiology Systems, Inc. | Abrasive drive shaft device for directional rotational atherectomy |
US5312427A (en) * | 1992-10-16 | 1994-05-17 | Shturman Cardiology Systems, Inc. | Device and method for directional rotational atherectomy |
US5643297A (en) * | 1992-11-09 | 1997-07-01 | Endovascular Instruments, Inc. | Intra-artery obstruction clearing apparatus and methods |
US5437678A (en) * | 1992-11-30 | 1995-08-01 | Neomedix Corporation | Ophthalmic lens removal method and apparatus |
AU6436594A (en) | 1993-04-30 | 1994-11-21 | Px Holding S.A. | Device for removing tissue by means of endoscopy |
US5417703A (en) * | 1993-07-13 | 1995-05-23 | Scimed Life Systems, Inc. | Thrombectomy devices and methods of using same |
CA2127637C (en) | 1993-07-26 | 2006-01-03 | Scott Bair | Fluid jet surgical cutting tool |
DE4402467A1 (de) * | 1994-01-28 | 1995-08-03 | Wolf Gmbh Richard | Insufflationsgerät |
WO1996010366A1 (en) * | 1994-10-03 | 1996-04-11 | Heart Technology, Inc. | Transluminal thrombectomy apparatus |
DK0817594T3 (da) | 1995-03-28 | 2002-07-15 | Straub Medical Ag | Kateter til fjernelse af unormale aflejringer i humane blodkar |
US5876414A (en) | 1995-03-28 | 1999-03-02 | Straub Medical Ag | Catheter for detaching abnormal deposits from blood vessels in humans |
US5749357A (en) * | 1995-05-19 | 1998-05-12 | Linder; Gerald S. | Malleable introducer |
US5662671A (en) * | 1996-07-17 | 1997-09-02 | Embol-X, Inc. | Atherectomy device having trapping and excising means for removal of plaque from the aorta and other arteries |
US6080170A (en) * | 1996-07-26 | 2000-06-27 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US6569147B1 (en) * | 1996-07-26 | 2003-05-27 | Kensey Nash Corporation | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes |
US5779721A (en) * | 1996-07-26 | 1998-07-14 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other blood vessels |
US5897534A (en) * | 1996-08-29 | 1999-04-27 | Team Medical, Llc | Body fluids and solids drainage system |
US5743891A (en) * | 1996-10-25 | 1998-04-28 | Act Medical, Inc. | Subcutaneous safety catheter assembly |
US6494890B1 (en) | 1997-08-14 | 2002-12-17 | Shturman Cardiology Systems, Inc. | Eccentric rotational atherectomy device |
US20030144875A1 (en) * | 1997-09-06 | 2003-07-31 | Suffin Stephen C. | EEG prediction method for medication response |
US6056722A (en) * | 1997-09-18 | 2000-05-02 | Iowa-India Investments Company Limited Of Douglas | Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use |
US6156046A (en) | 1997-11-07 | 2000-12-05 | Prolifix Medical, Inc. | Methods and systems for treating obstructions in a body lumen |
US5947985A (en) * | 1997-11-12 | 1999-09-07 | Imran; Mir A. | Apparatus and method for cleaning diseased vein grafts |
US6001112A (en) | 1998-04-10 | 1999-12-14 | Endicor Medical, Inc. | Rotational atherectomy device |
US6482217B1 (en) | 1998-04-10 | 2002-11-19 | Endicor Medical, Inc. | Neuro thrombectomy catheter |
US6666874B2 (en) * | 1998-04-10 | 2003-12-23 | Endicor Medical, Inc. | Rotational atherectomy system with serrated cutting tip |
US6186975B1 (en) * | 1998-10-30 | 2001-02-13 | Suzuki Motor Corporation | Liquid conveying catheter |
US6818002B2 (en) * | 1999-02-02 | 2004-11-16 | Samuel Shiber | Vessel cleaner and barrier |
EP1870044B1 (en) | 1999-03-01 | 2009-07-29 | ev3 Endovascular, Inc. | Rotational atherectomy system with serrated cutting tip |
AU3741400A (en) | 1999-03-15 | 2000-10-04 | Prolifix Medical, Inc. | Shielded atherectomy device |
US6066153A (en) * | 1999-03-31 | 2000-05-23 | Lev; Avigdor | Device and method for resecting body tissues |
US6238405B1 (en) * | 1999-04-30 | 2001-05-29 | Edwards Lifesciences Corp. | Percutaneous material removal device and method |
US6206900B1 (en) * | 1999-06-11 | 2001-03-27 | The General Hospital Corporation | Clot evacuation catheter |
US6527520B2 (en) * | 1999-07-29 | 2003-03-04 | Jonathan B. Rosefsky | Ribbon drive pumping with centrifugal contaminant removal |
US6638233B2 (en) * | 1999-08-19 | 2003-10-28 | Fox Hollow Technologies, Inc. | Apparatus and methods for material capture and removal |
JP2001070438A (ja) * | 1999-09-02 | 2001-03-21 | Sentan Kagaku Gijutsu Incubation Center:Kk | 生体用精密スクリューポンプ |
US6454775B1 (en) * | 1999-12-06 | 2002-09-24 | Bacchus Vascular Inc. | Systems and methods for clot disruption and retrieval |
WO2001019444A1 (en) | 1999-09-17 | 2001-03-22 | Bacchus Vascular Inc. | Mechanical pump for removal of fragmented matter and methods of manufacture and use |
US6702830B1 (en) * | 1999-09-17 | 2004-03-09 | Bacchus Vascular, Inc. | Mechanical pump for removal of fragmented matter and methods of manufacture and use |
US6663613B1 (en) | 2000-01-25 | 2003-12-16 | Bacchus Vascular, Inc. | System and methods for clot dissolution |
US6929633B2 (en) * | 2000-01-25 | 2005-08-16 | Bacchus Vascular, Inc. | Apparatus and methods for clot dissolution |
US20010031981A1 (en) * | 2000-03-31 | 2001-10-18 | Evans Michael A. | Method and device for locating guidewire and treating chronic total occlusions |
CA2403925C (en) * | 2000-04-05 | 2008-09-16 | Stx Medical, Inc. | Intralumenal material removal systems and methods |
US6669662B1 (en) | 2000-12-27 | 2003-12-30 | Advanced Cardiovascular Systems, Inc. | Perfusion catheter |
US6635070B2 (en) * | 2001-05-21 | 2003-10-21 | Bacchus Vascular, Inc. | Apparatus and methods for capturing particulate material within blood vessels |
US6830556B2 (en) | 2002-01-08 | 2004-12-14 | Zimmer Orthopaedic Surgical Products, Inc. | Debridement extension providing irrigation and mechanical scrubbing for removal of dead, devitalized, or contaminated tissue from a wound |
CA2540566A1 (en) * | 2003-09-08 | 2005-03-17 | Microdialysis Ltd. | Endotherapy catheter |
US8920402B2 (en) * | 2004-04-27 | 2014-12-30 | The Spectranetics Corporation | Thrombectomy and soft debris removal device |
-
2007
- 2007-10-12 US US11/871,908 patent/US8920402B2/en active Active
-
2008
- 2008-08-14 JP JP2010528914A patent/JP5429714B2/ja active Active
- 2008-08-14 WO PCT/US2008/073171 patent/WO2009097008A1/en active Application Filing
- 2008-08-14 EP EP08871986.9A patent/EP2187815B1/en active Active
-
2014
- 2014-12-05 US US14/562,014 patent/US9808277B2/en active Active
-
2017
- 2017-09-16 US US15/706,691 patent/US10517633B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0380872A (ja) * | 1989-05-12 | 1991-04-05 | Samuel Shiber | アテレクトミイ装置 |
US20050240146A1 (en) * | 2004-04-27 | 2005-10-27 | Nash John E | Thrombectomy and soft debris removal device |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016529968A (ja) * | 2013-07-26 | 2016-09-29 | カーディオバスキュラー システムズ, インコーポレイテッド | 装置を交換することなくアテレクトミおよびその後のバルーン血管形成を行うための装置、システムおよび方法 |
WO2018051894A1 (ja) * | 2016-09-16 | 2018-03-22 | テルモ株式会社 | 医療デバイス |
JPWO2018051894A1 (ja) * | 2016-09-16 | 2019-06-27 | テルモ株式会社 | 医療デバイス |
US11241251B2 (en) | 2016-09-16 | 2022-02-08 | Terumo Kabushiki Kaisha | Medical device |
WO2019188656A1 (ja) * | 2018-03-29 | 2019-10-03 | テルモ株式会社 | 医療デバイスの制御装置及び流体の流量を制御する方法 |
JPWO2019188656A1 (ja) * | 2018-03-29 | 2021-04-01 | テルモ株式会社 | 医療デバイスの制御装置及び流体の流量を制御する方法 |
JP7241064B2 (ja) | 2018-03-29 | 2023-03-16 | テルモ株式会社 | 医療デバイスの制御装置及び流体の流量を制御する方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2187815A1 (en) | 2010-05-26 |
US8920402B2 (en) | 2014-12-30 |
US20150094748A1 (en) | 2015-04-02 |
US9808277B2 (en) | 2017-11-07 |
EP2187815B1 (en) | 2022-04-13 |
US20080097499A1 (en) | 2008-04-24 |
WO2009097008A1 (en) | 2009-08-06 |
EP2187815A4 (en) | 2017-05-10 |
US10517633B2 (en) | 2019-12-31 |
US20180000510A1 (en) | 2018-01-04 |
JP5429714B2 (ja) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5429714B2 (ja) | 血栓切除および軟質残屑物を除去する装置 | |
EP1747032B1 (en) | Thrombectomy and soft debris removal device | |
JP5722938B2 (ja) | アテローム切除術の装置および方法 | |
US10154854B2 (en) | Atherectomy devices and methods | |
US9668767B2 (en) | Atherectomy devices and methods | |
US8361094B2 (en) | Atherectomy devices and methods | |
US20110112563A1 (en) | Atherectomy devices and methods | |
US20140249554A1 (en) | Atherectomy devices and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110808 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110808 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20111021 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130510 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5429714 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |